BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gold DV, Gaedcke J, Ghadimi BM, Goggins M, Hruban RH, Liu M, Newsome G, Goldenberg DM. PAM4 enzyme immunoassay alone and in combination with CA 19-9 for the detection of pancreatic adenocarcinoma. Cancer 2013;119:522-8. [PMID: 22898932 DOI: 10.1002/cncr.27762] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Loosen SH, Neumann UP, Trautwein C, Roderburg C, Luedde T. Current and future biomarkers for pancreatic adenocarcinoma. Tumour Biol 2017;39:101042831769223. [DOI: 10.1177/1010428317692231] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 9.8] [Reference Citation Analysis]
2 Zhai S, Liu Y, Lu X, Qian H, Tang X, Cheng X, Wang Y, Shi Y, Deng X. INPP4B As A Prognostic And Diagnostic Marker Regulates Cell Growth Of Pancreatic Cancer Via Activating AKT. Onco Targets Ther 2019;12:8287-99. [PMID: 31632078 DOI: 10.2147/OTT.S223221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
3 Deng Y, Ma H, Hao J, Xie Q, Zhao R. MCM2 and NUSAP1 Are Potential Biomarkers for the Diagnosis and Prognosis of Pancreatic Cancer. Biomed Res Int 2020;2020:8604340. [PMID: 32420375 DOI: 10.1155/2020/8604340] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Hasan S, Jacob R, Manne U, Paluri R. Advances in pancreatic cancer biomarkers. Oncol Rev 2019;13:410. [PMID: 31044028 DOI: 10.4081/oncol.2019.410] [Cited by in Crossref: 39] [Cited by in F6Publishing: 30] [Article Influence: 19.5] [Reference Citation Analysis]
5 Jenkinson C, Earl J, Ghaneh P, Halloran C, Carrato A, Greenhalf W, Neoptolemos J, Costello E. Biomarkers for early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2015;9:305-315. [PMID: 25373768 DOI: 10.1586/17474124.2015.965145] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
6 Keane MG, Shah A, Pereira SP, Joshi D. Novel biomarkers and endoscopic techniques for diagnosing pancreaticobiliary malignancy. F1000Res. 2017;6:1643. [PMID: 28944047 DOI: 10.12688/f1000research.11371.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer. 2013;13:66-74. [PMID: 23222481 DOI: 10.1038/nrc3420] [Cited by in Crossref: 90] [Cited by in F6Publishing: 73] [Article Influence: 10.0] [Reference Citation Analysis]
8 Costa WL Jr, Mantoan H, Brito RH, Ribeiro HS, Diniz AL, Godoy AL, Farias IC, Begnami MD, Soares FA, Coimbra FJ. Pancreatic mucinous cystadenoma with serum CA 19-9 over 1,000,000 U/mL: a case report and review of the literature. World J Surg Oncol 2015;13:78. [PMID: 25888888 DOI: 10.1186/s12957-015-0476-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
9 Levink I, Bruno MJ, Cahen DL. Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives. Curr Treat Options Gastroenterol. 2018;16:316-332. [PMID: 30196428 DOI: 10.1007/s11938-018-0190-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
10 Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and its microenvironment. Nat Rev Gastroenterol Hepatol. 2013;10:607-620. [PMID: 23856888 DOI: 10.1038/nrgastro.2013.120] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 17.9] [Reference Citation Analysis]
11 Brezgyte G, Shah V, Jach D, Crnogorac-Jurcevic T. Non-Invasive Biomarkers for Earlier Detection of Pancreatic Cancer-A Comprehensive Review. Cancers (Basel) 2021;13:2722. [PMID: 34072842 DOI: 10.3390/cancers13112722] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Liu D, Chang CH, Gold DV, Goldenberg DM. Identification of PAM4 (clivatuzumab)-reactive epitope on MUC5AC: a promising biomarker and therapeutic target for pancreatic cancer. Oncotarget 2015;6:4274-85. [PMID: 25595893 DOI: 10.18632/oncotarget.2760] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
13 O'Neill RS, Stoita A. Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket? World J Gastroenterol 2021;27:4045-87. [PMID: 34326612 DOI: 10.3748/wjg.v27.i26.4045] [Reference Citation Analysis]
14 Han S, Jin G, Wang L, Li M, He C, Guo X, Zhu Q. The role of PAM4 in the management of pancreatic cancer: diagnosis, radioimmunodetection, and radioimmunotherapy. J Immunol Res 2014;2014:268479. [PMID: 24818166 DOI: 10.1155/2014/268479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kaur S, Smith LM, Patel A, Menning M, Watley DC, Malik SS, Krishn SR, Mallya K, Aithal A, Sasson AR, Johansson SL, Jain M, Singh S, Guha S, Are C, Raimondo M, Hollingsworth MA, Brand RE, Batra SK. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. Am J Gastroenterol. 2017;112:172-183. [PMID: 27845339 DOI: 10.1038/ajg.2016.482] [Cited by in Crossref: 55] [Cited by in F6Publishing: 52] [Article Influence: 11.0] [Reference Citation Analysis]
16 Manne A, Esnakula A, Abushahin L, Tsung A. Understanding the Clinical Impact of MUC5AC Expression on Pancreatic Ductal Adenocarcinoma. Cancers (Basel) 2021;13:3059. [PMID: 34205412 DOI: 10.3390/cancers13123059] [Reference Citation Analysis]
17 Igbinigie E, Guo F, Jiang SW, Kelley C, Li J. Dkk1 involvement and its potential as a biomarker in pancreatic ductal adenocarcinoma. Clin Chim Acta. 2019;488:226-234. [PMID: 30452897 DOI: 10.1016/j.cca.2018.11.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
18 Giannis D, Moris D, Barbas AS. Diagnostic, Predictive and Prognostic Molecular Biomarkers in Pancreatic Cancer: An Overview for Clinicians. Cancers (Basel) 2021;13:1071. [PMID: 33802340 DOI: 10.3390/cancers13051071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Andersen DK, Andren-Sandberg Å, Duell EJ, Goggins M, Korc M, Petersen GM, Smith JP, Whitcomb DC. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2013;42:1227-37. [PMID: 24152948 DOI: 10.1097/MPA.0b013e3182a9ad9d] [Cited by in Crossref: 98] [Cited by in F6Publishing: 52] [Article Influence: 14.0] [Reference Citation Analysis]
20 Huo Z, Zhai S, Weng Y, Qian H, Tang X, Shi Y, Deng X, Wang Y, Shen B. PRPF40A as a potential diagnostic and prognostic marker is upregulated in pancreatic cancer tissues and cell lines: an integrated bioinformatics data analysis. Onco Targets Ther 2019;12:5037-51. [PMID: 31303762 DOI: 10.2147/OTT.S206039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Su SB, Qin SY, Chen W, Luo W, Jiang HX. Carbohydrate antigen 19-9 for differential diagnosis of pancreatic carcinoma and chronic pancreatitis. World J Gastroenterol 2015;21:4323-33. [PMID: 25892884 DOI: 10.3748/wjg.v21.i14.4323] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
22 Moravec R, Divi R, Verma M. Detecting circulating tumor material and digital pathology imaging during pancreatic cancer progression. World J Gastrointest Oncol 2017;9:235-50. [PMID: 28656074 DOI: 10.4251/wjgo.v9.i6.235] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
23 Shi C, Merchant N, Newsome G, Goldenberg DM, Gold DV. Differentiation of pancreatic ductal adenocarcinoma from chronic pancreatitis by PAM4 immunohistochemistry. Arch Pathol Lab Med. 2014;138:220-228. [PMID: 24476519 DOI: 10.5858/arpa.2013-0056-oa] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
24 Kawada N, Tanaka S, Uehara H, Ohkawa K, Yamai T, Takada R, Shiroeda H, Arisawa T, Tomita Y. Potential use of point shear wave elastography for the pancreas: a single center prospective study. Eur J Radiol. 2014;83:620-624. [PMID: 24445135 DOI: 10.1016/j.ejrad.2013.11.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
25 Calanzani N, Druce PE, Snudden C, Milley KM, Boscott R, Behiyat D, Saji S, Martinez-Gutierrez J, Oberoi J, Funston G, Messenger M, Emery J, Walter FM. Identifying Novel Biomarkers Ready for Evaluation in Low-Prevalence Populations for the Early Detection of Upper Gastrointestinal Cancers: A Systematic Review. Adv Ther 2021;38:793-834. [PMID: 33306189 DOI: 10.1007/s12325-020-01571-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Gold DV, Newsome G, Liu D, Goldenberg DM. Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin. Mol Cancer 2013;12:143. [PMID: 24257318 DOI: 10.1186/1476-4598-12-143] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.5] [Reference Citation Analysis]
27 Yako YY, Kruger D, Smith M, Brand M. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS One. 2016;11:e0154016. [PMID: 27170998 DOI: 10.1371/journal.pone.0154016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]